Cargando…
The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes
Exposure histories to SARS-CoV-2 variants and vaccinations will shape the specificity of antibody responses. To understand the specificity of Delta-elicited antibody immunity, we characterize the polyclonal antibody response elicited by primary or mRNA vaccine-breakthrough Delta infections. Both typ...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936118/ https://www.ncbi.nlm.nih.gov/pubmed/35313588 http://dx.doi.org/10.1101/2022.03.12.484088 |
_version_ | 1784672157017571328 |
---|---|
author | Greaney, Allison J. Eguia, Rachel T. Starr, Tyler N. Khan, Khadija Franko, Nicholas Logue, Jennifer K. Lord, Sandra M. Speake, Cate Chu, Helen Y. Sigal, Alex Bloom, Jesse D. |
author_facet | Greaney, Allison J. Eguia, Rachel T. Starr, Tyler N. Khan, Khadija Franko, Nicholas Logue, Jennifer K. Lord, Sandra M. Speake, Cate Chu, Helen Y. Sigal, Alex Bloom, Jesse D. |
author_sort | Greaney, Allison J. |
collection | PubMed |
description | Exposure histories to SARS-CoV-2 variants and vaccinations will shape the specificity of antibody responses. To understand the specificity of Delta-elicited antibody immunity, we characterize the polyclonal antibody response elicited by primary or mRNA vaccine-breakthrough Delta infections. Both types of infection elicit a neutralizing antibody response focused heavily on the receptor-binding domain (RBD). We use deep mutational scanning to show that mutations to the RBD’s class 1 and class 2 epitopes, including sites 417, 478, and 484–486 often reduce binding of these Delta-elicited antibodies. The anti-Delta antibody response is more similar to that elicited by early 2020 viruses than the Beta variant, with mutations to the class 1 and 2, but not class 3 epitopes, having the largest effects on polyclonal antibody binding. In addition, mutations to the class 1 epitope (e.g., K417N) tend to have larger effects on antibody binding and neutralization in the Delta spike than in the D614G spike, both for vaccine- and Delta-infection-elicited antibodies. These results help elucidate how the antigenic impacts of SARS-CoV-2 mutations depend on exposure history. |
format | Online Article Text |
id | pubmed-8936118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-89361182022-03-22 The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes Greaney, Allison J. Eguia, Rachel T. Starr, Tyler N. Khan, Khadija Franko, Nicholas Logue, Jennifer K. Lord, Sandra M. Speake, Cate Chu, Helen Y. Sigal, Alex Bloom, Jesse D. bioRxiv Article Exposure histories to SARS-CoV-2 variants and vaccinations will shape the specificity of antibody responses. To understand the specificity of Delta-elicited antibody immunity, we characterize the polyclonal antibody response elicited by primary or mRNA vaccine-breakthrough Delta infections. Both types of infection elicit a neutralizing antibody response focused heavily on the receptor-binding domain (RBD). We use deep mutational scanning to show that mutations to the RBD’s class 1 and class 2 epitopes, including sites 417, 478, and 484–486 often reduce binding of these Delta-elicited antibodies. The anti-Delta antibody response is more similar to that elicited by early 2020 viruses than the Beta variant, with mutations to the class 1 and 2, but not class 3 epitopes, having the largest effects on polyclonal antibody binding. In addition, mutations to the class 1 epitope (e.g., K417N) tend to have larger effects on antibody binding and neutralization in the Delta spike than in the D614G spike, both for vaccine- and Delta-infection-elicited antibodies. These results help elucidate how the antigenic impacts of SARS-CoV-2 mutations depend on exposure history. Cold Spring Harbor Laboratory 2022-03-14 /pmc/articles/PMC8936118/ /pubmed/35313588 http://dx.doi.org/10.1101/2022.03.12.484088 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article Greaney, Allison J. Eguia, Rachel T. Starr, Tyler N. Khan, Khadija Franko, Nicholas Logue, Jennifer K. Lord, Sandra M. Speake, Cate Chu, Helen Y. Sigal, Alex Bloom, Jesse D. The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes |
title | The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes |
title_full | The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes |
title_fullStr | The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes |
title_full_unstemmed | The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes |
title_short | The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes |
title_sort | sars-cov-2 delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936118/ https://www.ncbi.nlm.nih.gov/pubmed/35313588 http://dx.doi.org/10.1101/2022.03.12.484088 |
work_keys_str_mv | AT greaneyallisonj thesarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT eguiarachelt thesarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT starrtylern thesarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT khankhadija thesarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT frankonicholas thesarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT loguejenniferk thesarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT lordsandram thesarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT speakecate thesarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT chuheleny thesarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT sigalalex thesarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT bloomjessed thesarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT greaneyallisonj sarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT eguiarachelt sarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT starrtylern sarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT khankhadija sarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT frankonicholas sarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT loguejenniferk sarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT lordsandram sarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT speakecate sarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT chuheleny sarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT sigalalex sarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes AT bloomjessed sarscov2deltavariantinducesanantibodyresponselargelyfocusedonclass1and2antibodyepitopes |